Burkina Faso vs Estonia: Access to anti-retroviral drugs, male
Burkina Faso
68.0%
in 2024
Estonia
68.0%
in 2022
Burkina Faso rank
73rd
Estonia rank
73rd
Access to anti-retroviral drugs, male over time
- Burkina Faso
- Estonia
How they compare
Burkina Faso currently reports 68.0% against 68.0% in Estonia, a difference of 0.0%.
The two have swapped places 2 times across 23 shared years of data; in 2000 it was Estonia ahead.
Burkina Faso ranks 73rd and Estonia ranks 73rd of 141 countries.
Estonia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Burkina Faso | Estonia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 9.1% | 9.7% | 0.6% | Estonia |
| 2010s | 40.3% | 53.6% | 13.3% | Estonia |
| 2020s | 56.7% | 68.3% | 11.7% | Estonia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Burkina Faso or Estonia?
- Burkina Faso, at 68.0% against 68.0% in Estonia as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Burkina Faso and Estonia?
- 0.0%, with Burkina Faso ahead.
- How many years of comparable data are there for Burkina Faso and Estonia?
- 23 years are reported by both, from 2000 to 2022.
- How do Burkina Faso and Estonia rank globally for access to anti-retroviral drugs, male?
- Burkina Faso ranks 73rd and Estonia ranks 73rd of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.